Lookup NU author(s): Dr Catharien Hilkens,
Professor John Isaacs
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Dendritic cells with tolerogenic function (tolDC) have become a promising immunotherapeutic tool for reinstating immune tolerance in rheumatoid arthritis (RA) and other autoimmune diseases. The concept underpinning tolDC therapy is that it specifically targets the pathogenic autoimmune response while leaving protective immunity intact. Findings from human in-vitro and mouse in-vivo studies have been translated into the development of clinical grade tolDC for the treatment of autoimmune disorders. Recently, two tolDC trials in RA and type I diabetes have been carried out and other trials are in progress or are imminent. In this review, we provide an update on tolDC therapy, in particular in relation to the treatment of RA, and discuss the challenges and the future perspectives of this new experimental immunotherapy.
Author(s): Hilkens CMU, Isaacs JD
Publication type: Review
Publication status: Published
Journal: Clinical & Experimental Immunology
Print publication date: 01/05/2013
Online publication date: 10/04/2013
Acceptance date: 14/11/2012
ISSN (print): 0009-9104
ISSN (electronic): 1365-2249